Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 2,610,000 shares, an increase of 24.9% from the March 31st total of 2,090,000 shares. Based on an average daily volume of 725,500 shares, the short-interest ratio is currently 3.6 days. Currently, 4.0% of the shares of the stock are sold short.
Wall Street Analyst Weigh In
Several research analysts have issued reports on the stock. Truist Financial decreased their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research note on Wednesday, April 3rd. Finally, JMP Securities reduced their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus price target of $44.89.
Read Our Latest Stock Analysis on IART
Institutional Investors Weigh In On Integra LifeSciences
Integra LifeSciences Stock Down 0.2 %
Shares of NASDAQ IART traded down $0.07 during mid-day trading on Tuesday, reaching $29.17. The company had a trading volume of 650,226 shares, compared to its average volume of 702,239. The stock has a fifty day moving average of $35.02 and a two-hundred day moving average of $38.71. Integra LifeSciences has a 12-month low of $27.18 and a 12-month high of $56.21. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of 35.14, a PEG ratio of 0.85 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the business earned $0.94 EPS. As a group, equities research analysts expect that Integra LifeSciences will post 3.19 EPS for the current year.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
- Five stocks we like better than Integra LifeSciences
- How to Invest in Small Cap StocksĀ
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Why Are Stock Sectors Important to Successful Investing?
- Hilton Demonstrates Asset Light is Right for Investors
- Business Services Stocks Investing
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.